FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Clinical Update - Debio-9902 SR (ZT-1) Implant for Alzheimer's Disease
March 15th, 2007
Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, announced its first patient has enrolled in the phase II study with DEBIO-9902 SR implants (formerly ZT-1), the first monthly sustained-release acteylcholinesterase (AChE) inhibitor being developed for Alzheimer's patients. The study will measure the safety and efficacy of DEBIO-9902 SR implants, in comparison to oral donepezil, in a clinical trial named 'BRAINz' (Better Recollection for Alzheimer's patients with ImplaNts of ZT-1). "This is a promising new therapeutic approach," said David Wilkinson, MARC, Moorgreen Hospital,...
Source: FDA Law Weekly (2007-03-15)
|
